Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cytosorbents Corp - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
CTSO
Nasdaq
3845
http://cytosorbents.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cytosorbents Corp
CytoSorbents to Present at Two Upcoming Investor Conferences
- May 19th, 2022 11:00 am
Cytosorbents Corporation (NASDAQ:CTSO): When Will It Breakeven?
- May 12th, 2022 3:58 pm
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook
- May 3rd, 2022 8:15 pm
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
- May 2nd, 2022 11:00 am
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorbâ„¢-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery
- Apr 29th, 2022 11:00 am
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress
- Apr 28th, 2022 11:00 am
CytoSorbents to Report First Quarter 2022 Operating and Financial Results
- Apr 19th, 2022 11:00 am
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World
- Apr 14th, 2022 11:00 am
Cytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 67% if they invested a year ago
- Apr 12th, 2022 3:21 pm
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program
- Apr 7th, 2022 11:00 am
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors
- Apr 5th, 2022 11:00 am
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)
- Mar 17th, 2022 11:00 am
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook
- Mar 8th, 2022 9:15 pm
We're Hopeful That Cytosorbents (NASDAQ:CTSO) Will Use Its Cash Wisely
- Feb 26th, 2022 12:09 pm
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results
- Feb 8th, 2022 12:00 pm
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences
- Feb 3rd, 2022 12:00 pm
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock
- Feb 1st, 2022 12:00 pm
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology
- Jan 24th, 2022 12:00 pm
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds
- Jan 18th, 2022 3:57 pm
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue
- Jan 18th, 2022 12:00 pm
Scroll